You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSevoflurane
Accession NumberDB01236  (APRD00219)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionSevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia]
Structure
Thumb
Synonyms
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
Sevofluran
Sevoflurane
Sevoflurano
Sevofluranum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SevofluraneLiquid99.97 %Respiratory (inhalation)Baxter Corporation2007-04-11Not applicableCanada
Sevorane AFLiquid99.97 %Respiratory (inhalation)Abbvie Corporation1995-12-31Not applicableCanada
Sojourn SevofluraneLiquid99.97 %Respiratory (inhalation)Piramal Critical Care Inc2009-11-18Not applicableCanada
UltaneLiquid250 mL/250mLRespiratory (inhalation)Abb Vie Inc.1995-06-07Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Baxter Healthcare Corporation2011-10-18Not applicableUs
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Baxter Healthcare Corporation2002-07-07Not applicableUs
SevofluraneLiquid1 mL/mLRespiratory (inhalation)Piramal Critical Care Inc2011-07-15Not applicableUs
SevofluraneLiquid250 mL/250mLRespiratory (inhalation)Sandoz Inc.2015-11-032016-10-13Us
SojournLiquid1 mL/mLRespiratory (inhalation)Piramal Critical Care Inc2010-04-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
SevoraneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII38LVP0K73A
CAS number28523-86-6
WeightAverage: 200.0548
Monoisotopic: 200.007212153
Chemical FormulaC4H3F7O
InChI KeyDFEYYRMXOJXZRJ-UHFFFAOYSA-N
InChI
InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2
IUPAC Name
1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
SMILES
FCOC(C(F)(F)F)C(F)(F)F
Pharmacology
IndicationUsed for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Structured Indications Not Available
PharmacodynamicsSevoflurane (also called fluoromethyl) is a halogenated ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. It is often administered in nitrous oxide and pure oxygen. After desflurane it is the volatile anesthetic with the fastest onset and offset. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
Mechanism of actionSevoflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Sevoflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase and also binds to the GABA receptor, the large conductance Ca2+ activated potassium channel, the glutamate receptor, and the glycine receptor.
TargetKindPharmacological actionActionsOrganismUniProt ID
Gamma-aminobutyric acid receptor subunit alpha-1Proteinyes
agonist
HumanP14867 details
Glycine receptor subunit alpha-1Proteinyes
agonist
HumanP23415 details
Glutamate receptor 1Proteinyes
antagonist
HumanP42261 details
Potassium voltage-gated channel subfamily A member 1Proteinyes
inducer
HumanQ09470 details
Calcium-transporting ATPase type 2C member 1Proteinyes
inhibitor
HumanP98194 details
ATP synthase subunit delta, mitochondrialProteinunknown
other/unknown
HumanP30049 details
NADH-ubiquinone oxidoreductase chain 1Proteinunknown
unknown
HumanP03886 details
GABA-A receptor (anion channel)Protein groupyes
positive allosteric modulator
Humannot applicabledetails
Related Articles
AbsorptionRapidly absorbed into circulation via the lungs, however solubility in the blood is low.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Relatively little biotransformation, only 5% is metabolized by cytochrome P450 CYP2E1 to hexafluoroisopropanol (HFIP) with release of inorganic fluoride and CO2. No other metabolic pathways have been identified for sevoflurane.

SubstrateEnzymesProduct
Sevoflurane
Not Available
FluorideDetails
Sevoflurane
Not Available
Carbon dioxideDetails
Sevoflurane
Not Available
HexafluoroisopropanolDetails
Route of eliminationThe low solubility of sevoflurane facilitates rapid elimination via the lungs. In vivo metabolism studies suggest that approximately 5% of the sevoflurane dose may be metabolized. Up to 3.5% of the sevoflurane dose appears in the urine as inorganic fluoride.
Half life15-23 hours
ClearanceNot Available
ToxicityLC50=49881 ppm/hr (rat), LD50=10.8 g/kg (rat)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with 7-Nitroindazole.Experimental
AbciximabSevoflurane may increase the anticoagulant activities of Abciximab.Approved
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Sevoflurane.Approved
AcenocoumarolSevoflurane may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Acetylsalicylic acid.Approved, Vet Approved
adipiplonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sevoflurane.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Sevoflurane.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Sevoflurane.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sevoflurane.Approved, Illicit, Investigational
AlprostadilAlprostadil may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
AlteplaseSevoflurane may increase the anticoagulant activities of Alteplase.Approved
ALX-0081Sevoflurane may increase the anticoagulant activities of ALX-0081.Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Sevoflurane.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Sevoflurane.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Aminosalicylic Acid.Approved
AmiodaroneThe metabolism of Sevoflurane can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sevoflurane.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Amperozide.Experimental
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sevoflurane.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Sevoflurane.Approved
AnagrelideSevoflurane may increase the QTc-prolonging activities of Anagrelide.Approved
AncrodSevoflurane may increase the anticoagulant activities of Ancrod.Investigational
AnistreplaseSevoflurane may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanSevoflurane may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Apixaban.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Sevoflurane.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Sevoflurane.Approved
AprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Aprepitant.Approved, Investigational
ArdeparinSevoflurane may increase the anticoagulant activities of Ardeparin.Approved, Withdrawn
ArgatrobanSevoflurane may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sevoflurane.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sevoflurane.Approved
Arsenic trioxideSevoflurane may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherSevoflurane may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Articaine.Approved
AsenapineSevoflurane may increase the QTc-prolonging activities of Asenapine.Approved
AstaxanthinSevoflurane may increase the anticoagulant activities of Astaxanthin.Investigational
AtazanavirThe metabolism of Sevoflurane can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Sevoflurane.Approved
AtomoxetineThe metabolism of Sevoflurane can be decreased when combined with Atomoxetine.Approved
Atracurium besylateSevoflurane may increase the neuromuscular blocking activities of Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azaperone.Vet Approved
AzelastineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sevoflurane.Approved
AzithromycinSevoflurane may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Baclofen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Sevoflurane.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sevoflurane.Approved
BatroxobinSevoflurane may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminSevoflurane may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BedaquilineSevoflurane may increase the QTc-prolonging activities of Bedaquiline.Approved
BemiparinSevoflurane may increase the anticoagulant activities of Bemiparin.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sevoflurane.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Sevoflurane.Approved
BenperidolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Sevoflurane.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sevoflurane.Approved, Withdrawn
BeraprostSevoflurane may increase the anticoagulant activities of Beraprost.Investigational
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Sevoflurane.Approved
BexaroteneThe serum concentration of Sevoflurane can be decreased when it is combined with Bexarotene.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Sevoflurane.Approved
BivalirudinSevoflurane may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Sevoflurane can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Sevoflurane can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sevoflurane can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Sevoflurane.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
BromazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sevoflurane.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Brotizolam.Approved, Withdrawn
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Sevoflurane.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sevoflurane.Approved, Investigational
BuprenorphineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sevoflurane.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sevoflurane.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.Approved, Illicit, Vet Approved
ButylphthalideSevoflurane may increase the antiplatelet activities of Butylphthalide.Investigational
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Sevoflurane.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Sevoflurane.Approved
CangrelorSevoflurane may increase the anticoagulant activities of Cangrelor.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Sevoflurane.Approved
CarbamazepineThe metabolism of Sevoflurane can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sevoflurane.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Sevoflurane.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Sevoflurane.Approved, Investigational
CeritinibThe serum concentration of Sevoflurane can be increased when it is combined with Ceritinib.Approved
CertoparinSevoflurane may increase the anticoagulant activities of Certoparin.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sevoflurane.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Sevoflurane.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sevoflurane.Approved
ChloroquineSevoflurane may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Sevoflurane.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorphenamine.Approved
ChlorpromazineSevoflurane may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Sevoflurane.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sevoflurane.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sevoflurane.Approved
CilostazolSevoflurane may increase the anticoagulant activities of Cilostazol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sevoflurane.Approved, Vet Approved
CiprofloxacinSevoflurane may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideSevoflurane may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramSevoflurane may increase the QTc-prolonging activities of Citalopram.Approved
Citric AcidSevoflurane may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Sevoflurane can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sevoflurane can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sevoflurane.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sevoflurane.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Clonidine.Approved
ClopidogrelThe metabolism of Sevoflurane can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sevoflurane.Approved, Illicit
ClotrimazoleThe metabolism of Sevoflurane can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineSevoflurane may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe metabolism of Sevoflurane can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Sevoflurane.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sevoflurane.Approved, Illicit
CollagenaseThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Collagenase.Approved
ConivaptanThe serum concentration of Sevoflurane can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibSevoflurane may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.Approved
CyclosporineThe metabolism of Sevoflurane can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Sevoflurane can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateSevoflurane may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Sevoflurane can be decreased when it is combined with Dabrafenib.Approved
DalteparinSevoflurane may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidSevoflurane may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DantroleneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sevoflurane.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sevoflurane.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dapoxetine.Investigational
DarunavirThe metabolism of Sevoflurane can be decreased when combined with Darunavir.Approved
DasatinibDasatinib may increase the anticoagulant activities of Sevoflurane.Approved, Investigational
DeferasiroxThe serum concentration of Sevoflurane can be decreased when it is combined with Deferasirox.Approved, Investigational
DefibrotideSevoflurane may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelavirdineThe metabolism of Sevoflurane can be decreased when combined with Delavirdine.Approved
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Deoxycholic Acid.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with deramciclane.Investigational
dersalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desipramine.Approved
DesirudinSevoflurane may increase the anticoagulant activities of Desirudin.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desloratadine.Approved, Investigational
DesmoteplaseSevoflurane may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Sevoflurane can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sevoflurane.Approved, Vet Approved
DextranSevoflurane may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Sevoflurane may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Sevoflurane may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Sevoflurane may increase the anticoagulant activities of Dextran 75.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sevoflurane.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Sevoflurane.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Sevoflurane.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sevoflurane.Approved
DicoumarolSevoflurane may increase the anticoagulant activities of Dicoumarol.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Difenoxin.Approved, Illicit
DiflunisalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Diflunisal.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Sevoflurane can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Sevoflurane can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sevoflurane.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Sevoflurane.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Sevoflurane.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sevoflurane.Approved
DisopyramideSevoflurane may increase the QTc-prolonging activities of Disopyramide.Approved
DisulfiramThe metabolism of Sevoflurane can be decreased when combined with Disulfiram.Approved
DitazoleSevoflurane may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DofetilideSevoflurane may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronSevoflurane may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneSevoflurane may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DopamineSevoflurane may increase the arrhythmogenic activities of Dopamine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sevoflurane.Approved
DoxepinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Doxepin.Approved
DoxorubicinThe metabolism of Sevoflurane can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Sevoflurane can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sevoflurane is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Illicit
DronedaroneSevoflurane may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Drotebanol.Experimental, Illicit
Drotrecogin alfaSevoflurane may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DuloxetineSevoflurane may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sevoflurane.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Sevoflurane is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ecopipam.Investigational
Edetic AcidSevoflurane may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanSevoflurane may increase the anticoagulant activities of Edoxaban.Approved
EfavirenzThe serum concentration of Sevoflurane can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Sevoflurane.Approved
EliglustatSevoflurane may increase the QTc-prolonging activities of Eliglustat.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sevoflurane.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sevoflurane.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sevoflurane.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sevoflurane.Approved, Vet Approved
EnoxaparinSevoflurane may increase the anticoagulant activities of Enoxaparin.Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Sevoflurane can be decreased when it is combined with Enzalutamide.Approved
EphedraEphedra may increase the arrhythmogenic activities of Sevoflurane.Approved, Nutraceutical, Withdrawn
EphedrineEphedrine may increase the arrhythmogenic activities of Sevoflurane.Approved
EpinastineEpinastine may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
EpinephrineSevoflurane may increase the arrhythmogenic activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Sevoflurane.Approved
eplivanserineSevoflurane may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sevoflurane.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sevoflurane.Approved
EptifibatideSevoflurane may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
ErythromycinSevoflurane may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramSevoflurane may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Sevoflurane can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Sevoflurane.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Sevoflurane.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sevoflurane.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sevoflurane.Approved
EthanolSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sevoflurane.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethotoin.Approved
Ethyl biscoumacetateSevoflurane may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sevoflurane.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Sevoflurane can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Sevoflurane.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sevoflurane.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Sevoflurane.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fexofenadine.Approved
FibrinolysinSevoflurane may increase the anticoagulant activities of Fibrinolysin.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sevoflurane.Approved
FlecainideSevoflurane may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flibanserin.Approved
FluconazoleThe metabolism of Sevoflurane can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fludiazepam.Approved, Illicit
FluindioneSevoflurane may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Flunitrazepam.Approved, Illicit
FluoxetineSevoflurane may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolSevoflurane may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sevoflurane.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sevoflurane.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Sevoflurane can be decreased when combined with Fluvoxamine.Approved, Investigational
FondaparinuxSevoflurane may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumSevoflurane may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormoterolSevoflurane may increase the arrhythmogenic activities of Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Sevoflurane can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sevoflurane can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sevoflurane.Approved
FosphenytoinThe metabolism of Sevoflurane can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Sevoflurane.Approved, Vet Approved
Fusidic AcidThe serum concentration of Sevoflurane can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Sevoflurane.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with gabapentin enacarbil.Approved
GabexateSevoflurane may increase the anticoagulant activities of Gabexate.Investigational
Gadobenic acidSevoflurane may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GemifloxacinSevoflurane may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Gepirone.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Sevoflurane.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Glutethimide.Approved, Illicit
GoserelinSevoflurane may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronSevoflurane may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Sevoflurane.Approved, Illicit, Withdrawn
HaloperidolSevoflurane may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Sevoflurane.Approved, Vet Approved
HeparinSevoflurane may increase the anticoagulant activities of Heparin.Approved, Investigational
HeroinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Hexobarbital.Approved
HigenamineSevoflurane may increase the anticoagulant activities of Higenamine.Investigational
HirulogSevoflurane may increase the anticoagulant activities of Hirulog.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sevoflurane.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Sevoflurane.Approved, Vet Approved
HydrocodoneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Sevoflurane.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sevoflurane.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Sevoflurane.Approved
IbudilastSevoflurane may increase the antiplatelet activities of Ibudilast.Approved, Investigational
IbutilideSevoflurane may increase the QTc-prolonging activities of Ibutilide.Approved
Icosapent ethylSevoflurane may increase the antiplatelet activities of Icosapent ethyl.Approved, Nutraceutical
IdelalisibThe serum concentration of Sevoflurane can be increased when it is combined with Idelalisib.Approved
idraparinuxSevoflurane may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilSevoflurane may increase the antiplatelet activities of Ifenprodil.Approved, Withdrawn
IloperidoneSevoflurane may increase the QTc-prolonging activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Sevoflurane.Approved, Investigational
ImatinibThe metabolism of Sevoflurane can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sevoflurane.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Sevoflurane.Approved
IndinavirThe metabolism of Sevoflurane can be decreased when combined with Indinavir.Approved
IndobufenSevoflurane may increase the anticoagulant activities of Indobufen.Investigational
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sevoflurane.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sevoflurane.Approved, Investigational
IsavuconazoniumThe metabolism of Sevoflurane can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Sevoflurane.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Sevoflurane.Approved, Vet Approved
IsoniazidThe metabolism of Sevoflurane can be decreased when combined with Isoniazid.Approved
IsoprenalineSevoflurane may increase the arrhythmogenic activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sevoflurane.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sevoflurane.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Sevoflurane.Approved, Withdrawn
IsradipineThe metabolism of Sevoflurane can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sevoflurane can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Sevoflurane can be increased when it is combined with Ivacaftor.Approved
Kct 0809Sevoflurane may increase the anticoagulant activities of Kct 0809.Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Sevoflurane.Approved, Vet Approved
KetanserinSevoflurane may increase the antiplatelet activities of Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Sevoflurane can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Sevoflurane.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sevoflurane.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lamotrigine.Approved, Investigational
LenvatinibSevoflurane may increase the QTc-prolonging activities of Lenvatinib.Approved
LepirudinSevoflurane may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sevoflurane.Approved, Investigational
LeuprolideSevoflurane may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Sevoflurane.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Sevoflurane.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levocetirizine.Approved
LevodopaSevoflurane may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinSevoflurane may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Sevoflurane.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Sevoflurane.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Sevoflurane.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sevoflurane.Approved, Vet Approved
LimaprostLimaprost may increase the antiplatelet activities of Sevoflurane.Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sevoflurane.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Sevoflurane.Approved, Investigational
LopinavirThe metabolism of Sevoflurane can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sevoflurane.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Sevoflurane.Approved
LovastatinThe metabolism of Sevoflurane can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sevoflurane.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Sevoflurane is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Sevoflurane can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Sevoflurane can be decreased when it is combined with Lumacaftor.Approved
LumefantrineSevoflurane may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Sevoflurane.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Maprotiline.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sevoflurane.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Sevoflurane.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Sevoflurane.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sevoflurane.Approved, Illicit
MesalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Mesalazine.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Sevoflurane.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.Approved
MethadoneSevoflurane may increase the QTc-prolonging activities of Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Sevoflurane.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sevoflurane.Approved
MethotrimeprazineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Sevoflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Sevoflurane.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Sevoflurane.Approved
MethylphenidateMethylphenidate may increase the hypertensive activities of Sevoflurane.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Sevoflurane.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Sevoflurane.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Sevoflurane.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sevoflurane.Approved, Investigational
MetyrosineSevoflurane may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sevoflurane.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Sevoflurane.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Milnacipran.Approved
MilrinoneMilrinone may increase the antiplatelet activities of Sevoflurane.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sevoflurane.Approved
MirtazapineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Sevoflurane can be decreased when it is combined with Mitotane.Approved
MivacuriumSevoflurane may increase the neuromuscular blocking activities of Mivacurium.Approved
ModafinilThe serum concentration of Sevoflurane can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sevoflurane.Approved
MolindoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sevoflurane.Approved, Investigational
MoxifloxacinSevoflurane may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Sevoflurane.Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Sevoflurane.Approved
NadroparinSevoflurane may increase the anticoagulant activities of Nadroparin.Approved
NafamostatSevoflurane may increase the anticoagulant activities of Nafamostat.Investigational
NafcillinThe serum concentration of Sevoflurane can be decreased when it is combined with Nafcillin.Approved
NaftopidilSevoflurane may increase the antiplatelet activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Sevoflurane.Approved
NCX 4016The risk or severity of adverse effects can be increased when Sevoflurane is combined with NCX 4016.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Sevoflurane.Approved, Investigational
NefazodoneThe metabolism of Sevoflurane can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sevoflurane can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Sevoflurane.Approved, Investigational
NetupitantThe serum concentration of Sevoflurane can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sevoflurane can be increased when combined with Nevirapine.Approved
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sevoflurane.Approved
NicorandilNicorandil may increase the hypotensive activities of Sevoflurane.Approved
NicotineThe metabolism of Sevoflurane can be decreased when combined with Nicotine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sevoflurane.Approved
NilotinibSevoflurane may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sevoflurane.Approved
NimesulideSevoflurane may increase the antiplatelet activities of Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sevoflurane.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sevoflurane.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sevoflurane.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sevoflurane.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sevoflurane.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sevoflurane.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineSevoflurane may increase the arrhythmogenic activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Nortriptyline.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Obinutuzumab.Approved
OfloxacinSevoflurane may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sevoflurane.Approved, Investigational
OlaparibThe metabolism of Sevoflurane can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sevoflurane.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olopatadine.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Sevoflurane.Approved
OndansetronSevoflurane may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Opium.Approved, Illicit
OrphenadrineSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Sevoflurane can be increased when it is combined with Osimertinib.Approved
OtamixabanSevoflurane may increase the anticoagulant activities of Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Sevoflurane.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Sevoflurane.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sevoflurane.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Sevoflurane.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sevoflurane.Approved, Vet Approved
PalbociclibThe serum concentration of Sevoflurane can be increased when it is combined with Palbociclib.Approved
PaliperidoneSevoflurane may increase the QTc-prolonging activities of Paliperidone.Approved
PanobinostatSevoflurane may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Sevoflurane.Approved
ParaldehydeSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParnaparinSevoflurane may increase the anticoagulant activities of Parnaparin.Approved
ParoxetineThe metabolism of Sevoflurane can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibSevoflurane may increase the QTc-prolonging activities of Pazopanib.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Sevoflurane.Approved, Investigational
PentamidineSevoflurane may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Sevoflurane.Approved, Vet Approved
PentobarbitalThe metabolism of Sevoflurane can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
PerazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perazine.Investigational
PerflutrenSevoflurane may increase the QTc-prolonging activities of Perflutren.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sevoflurane.Approved
PerospironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Sevoflurane.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sevoflurane.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Sevoflurane.Approved
PhenindioneSevoflurane may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Sevoflurane can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sevoflurane.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenoxyethanol.Approved
PhenprocoumonSevoflurane may increase the anticoagulant activities of Phenprocoumon.Approved
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Sevoflurane.Approved
PhenytoinThe metabolism of Sevoflurane can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideSevoflurane may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Sevoflurane.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pizotifen.Approved
PlasminSevoflurane may increase the anticoagulant activities of Plasmin.Investigational
PomalidomideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Sevoflurane can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleSevoflurane may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pramocaine.Approved
PrasugrelSevoflurane may increase the anticoagulant activities of Prasugrel.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Sevoflurane.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sevoflurane.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Sevoflurane.Approved
PrimaquineSevoflurane may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Sevoflurane can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideSevoflurane may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Sevoflurane.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.Approved, Vet Approved
PromazineSevoflurane may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Promethazine.Approved
PropafenoneSevoflurane may increase the QTc-prolonging activities of Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Sevoflurane.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Sevoflurane.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Sevoflurane.Approved, Investigational
Protein CSevoflurane may increase the anticoagulant activities of Protein C.Approved
Protein S humanSevoflurane may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeSevoflurane may increase the anticoagulant activities of Protocatechualdehyde.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Sevoflurane is combined with PSD502.Investigational
QuazepamThe serum concentration of Sevoflurane can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineSevoflurane may increase the QTc-prolonging activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sevoflurane.Approved, Investigational
QuinidineSevoflurane may increase the QTc-prolonging activities of Quinidine.Approved
QuinineSevoflurane may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Raclopride.Investigational
RamatrobanSevoflurane may increase the antiplatelet activities of Ramatroban.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sevoflurane.Approved
RanolazineThe metabolism of Sevoflurane can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumSevoflurane may increase the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Sevoflurane.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Sevoflurane.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sevoflurane.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sevoflurane.Approved
ResveratrolSevoflurane may increase the antiplatelet activities of Resveratrol.Experimental, Investigational
ReteplaseSevoflurane may increase the anticoagulant activities of Reteplase.Approved
ReviparinSevoflurane may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the antiplatelet activities of Sevoflurane.Approved
RifabutinThe metabolism of Sevoflurane can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sevoflurane can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sevoflurane can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Sevoflurane.Approved
RisperidoneSevoflurane may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ritanserin.Investigational
RitonavirThe metabolism of Sevoflurane can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanSevoflurane may increase the anticoagulant activities of Rivaroxaban.Approved
RomifidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Romifidine.Vet Approved
RopiniroleSevoflurane may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sevoflurane.Approved
RosiglitazoneSevoflurane may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineSevoflurane may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sevoflurane.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Sevoflurane is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sevoflurane.Approved
Sage 547The risk or severity of adverse effects can be increased when Sevoflurane is combined with Sage 547.Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Sevoflurane can be decreased when combined with Saquinavir.Approved, Investigational
SCH-530348Sevoflurane may increase the antiplatelet activities of SCH-530348.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sevoflurane.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Sevoflurane.Approved, Investigational, Vet Approved
SelexipagSevoflurane may increase the anticoagulant activities of Selexipag.Approved
SertindoleThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sertindole.Approved, Withdrawn
SertralineThe metabolism of Sevoflurane can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Sevoflurane can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sevoflurane can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sevoflurane can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
SorafenibThe metabolism of Sevoflurane can be decreased when combined with Sorafenib.Approved, Investigational
SotalolSevoflurane may increase the QTc-prolonging activities of Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Sevoflurane.Approved
SRT501Sevoflurane may increase the antiplatelet activities of SRT501.Investigational
St. John's WortThe serum concentration of Sevoflurane can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sevoflurane can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.Approved, Investigational
SulfisoxazoleSevoflurane may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulodexideSevoflurane may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sevoflurane.Approved
SuvorexantSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Sevoflurane can be decreased when combined with Telaprevir.Approved
TelavancinSevoflurane may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Sevoflurane can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sevoflurane.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sevoflurane.Approved
TenecteplaseSevoflurane may increase the anticoagulant activities of Tenecteplase.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Sevoflurane.Approved
TesmilifeneSevoflurane may increase the antiplatelet activities of Tesmilifene.Investigational
TetrabenazineSevoflurane may increase the QTc-prolonging activities of Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tetrodotoxin.Investigational
ThalidomideSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Sevoflurane.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sevoflurane.Approved, Vet Approved
ThioridazineSevoflurane may increase the QTc-prolonging activities of Thioridazine.Approved
ThiotepaThe metabolism of Sevoflurane can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiapride.Investigational
TicagrelorSevoflurane may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineThe metabolism of Sevoflurane can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Sevoflurane.Approved
TinzaparinSevoflurane may increase the anticoagulant activities of Tinzaparin.Approved
TipranavirTipranavir may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
TirofibanSevoflurane may increase the anticoagulant activities of Tirofiban.Approved
TizanidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Sevoflurane can be decreased when it is combined with Tocilizumab.Approved
TolazolineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Sevoflurane.Approved
ToremifeneSevoflurane may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tositumomab.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sevoflurane.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sevoflurane.Approved
TranilastSevoflurane may increase the antiplatelet activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sevoflurane.Approved
TrapidilSevoflurane may increase the antiplatelet activities of Trapidil.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sevoflurane.Approved, Investigational
TreprostinilTreprostinil may increase the antiplatelet activities of Sevoflurane.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Sevoflurane.Approved
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Sevoflurane.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sevoflurane.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sevoflurane.Approved, Vet Approved
TriflusalSevoflurane may increase the anticoagulant activities of Triflusal.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Sevoflurane is combined with Uc1010.Investigational
UrokinaseSevoflurane may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sevoflurane.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sevoflurane.Approved, Investigational
VandetanibSevoflurane may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibSevoflurane may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Sevoflurane can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Sevoflurane can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vigabatrin.Approved
Vitamin EVitamin E may increase the antiplatelet activities of Sevoflurane.Approved, Nutraceutical, Vet Approved
VorapaxarSevoflurane may increase the anticoagulant activities of Vorapaxar.Approved
VoriconazoleThe metabolism of Sevoflurane can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vortioxetine.Approved
WarfarinSevoflurane may increase the anticoagulant activities of Warfarin.Approved
XimelagatranSevoflurane may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Xylazine.Vet Approved
Ym150Sevoflurane may increase the anticoagulant activities of Ym150.Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Sevoflurane.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zimelidine.Withdrawn
ZiprasidoneSevoflurane may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zolazepam.Vet Approved
ZolpidemSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Sevoflurane.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Zotepine.Approved
ZuclopenthixolSevoflurane may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Ross C. Terrell, “Method for the preparation of sevoflurane.” U.S. Patent US5969193, issued December, 1979.

US5969193
General ReferencesNot Available
External Links
ATC CodesN01AB08
AHFS Codes
  • 28:04.00
PDB EntriesNot Available
FDA labelDownload (188 KB)
MSDSDownload (49.5 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9963
Blood Brain Barrier+0.9941
Caco-2 permeable+0.6134
P-glycoprotein substrateNon-substrate0.8839
P-glycoprotein inhibitor INon-inhibitor0.8807
P-glycoprotein inhibitor IINon-inhibitor0.5436
Renal organic cation transporterNon-inhibitor0.8649
CYP450 2C9 substrateNon-substrate0.9039
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6876
CYP450 1A2 substrateInhibitor0.5254
CYP450 2C9 inhibitorNon-inhibitor0.7941
CYP450 2D6 inhibitorNon-inhibitor0.9114
CYP450 2C19 inhibitorInhibitor0.5569
CYP450 3A4 inhibitorNon-inhibitor0.9148
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7006
Ames testAMES toxic0.5082
CarcinogenicityCarcinogens 0.7014
BiodegradationNot ready biodegradable0.8564
Rat acute toxicity1.3361 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9485
hERG inhibition (predictor II)Non-inhibitor0.8685
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
LiquidRespiratory (inhalation)250 mL/250mL
LiquidRespiratory (inhalation)99.97 %
LiquidRespiratory (inhalation)1 mL/mL
Prices
Unit descriptionCostUnit
Ultane 250 ml pen bottle1.16USD ml
Sojourn inhalation liquid0.99USD ml
Sevoflurane inhalation liquid0.89USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5990176 Yes1997-07-272017-07-27Us
US6074668 Yes1998-07-092018-07-09Us
US6288127 Yes1997-07-272017-07-27Us
US6444859 Yes1997-07-272017-07-27Us
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point58.5 °CPhysProp
water solubilityVery slightly solubleNot Available
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.48 mg/mLALOGPS
logP2.44ALOGPS
logP2.27ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)15.07ChemAxon
pKa (Strongest Basic)-4.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.23 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity23.3 m3·mol-1ChemAxon
Polarizability9.83 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dialkyl ethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are alkyl groups.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassEthers
Sub ClassDialkyl ethers
Direct ParentDialkyl ethers
Alternative Parents
Substituents
  • Dialkyl ether
  • Halomethane
  • Hydrocarbon derivative
  • Organofluoride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Transmitter-gated ion channel activity
Specific Function:
The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
Gene Name:
GLRA1
Uniprot ID:
P23415
Molecular Weight:
52623.35 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Pdz domain binding
Specific Function:
Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a conformation change, leading to the opening of the cation channel, and thereby converts the chemical signal to an electrical impulse. The receptor then desensitizes rapidly and enters a transient inacti...
Gene Name:
GRIA1
Uniprot ID:
P42261
Molecular Weight:
101505.245 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Voltage-gated potassium channel activity
Specific Function:
Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:19903818). Contributes to the regulation of the membrane potential and nerve signaling, and prevents neuronal hyperexcitability (PubMed:17156368). Forms tetrameric potassium-selective channels through which ...
Gene Name:
KCNA1
Uniprot ID:
Q09470
Molecular Weight:
56465.01 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Signal transducer activity
Specific Function:
This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
Gene Name:
ATP2C1
Uniprot ID:
P98194
Molecular Weight:
100576.42 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Transporter activity
Specific Function:
Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport complexes of the respiratory chain. F-type ATPases consist of two structural domains, F(1) - containing the extramembraneous catalytic core, and F(0) - containing the membrane proton channel, linked toget...
Gene Name:
ATP5D
Uniprot ID:
P30049
Molecular Weight:
17489.755 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
unknown
General Function:
Nadh dehydrogenase (ubiquinone) activity
Specific Function:
Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the transfer of electrons from NADH to the respiratory chain. The immediate electron acceptor for the enzyme is believed to be ubiquinone (By similarity).
Gene Name:
MT-ND1
Uniprot ID:
P03886
Molecular Weight:
35660.055 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein group
Organism
Human
Pharmacological action
yes
Actions
positive allosteric modulator
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By similarity).
Components:
NameUniProt IDDetails
Gamma-aminobutyric acid receptor subunit alpha-1P14867 Details
Gamma-aminobutyric acid receptor subunit alpha-2P47869 Details
Gamma-aminobutyric acid receptor subunit alpha-3P34903 Details
Gamma-aminobutyric acid receptor subunit alpha-4P48169 Details
Gamma-aminobutyric acid receptor subunit alpha-5P31644 Details
Gamma-aminobutyric acid receptor subunit alpha-6Q16445 Details
Gamma-aminobutyric acid receptor subunit beta-1P18505 Details
Gamma-aminobutyric acid receptor subunit beta-2P47870 Details
Gamma-aminobutyric acid receptor subunit beta-3P28472 Details
Gamma-aminobutyric acid receptor subunit deltaO14764 Details
Gamma-aminobutyric acid receptor subunit epsilonP78334 Details
Gamma-aminobutyric acid receptor subunit gamma-1Q8N1C3 Details
Gamma-aminobutyric acid receptor subunit gamma-2P18507 Details
Gamma-aminobutyric acid receptor subunit gamma-3Q99928 Details
Gamma-aminobutyric acid receptor subunit piO00591 Details
Gamma-aminobutyric acid receptor subunit thetaQ9UN88 Details
References
  1. ChEMBL Compound Report Card [Link]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
References
  1. Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 08, 2016 03:55